International Circulation:   Is this strategy something that is global?  You are from the European society but is this something that you think is equally applicable to hypertensive patients elsewhere， Chinese patients in Asia for instance?  An early intervention strategy rather than lower being better， is this something that we can apply to Chinese patients?

  《国际循环》：这一策略是全球性的吗？您来自欧洲协会，但您认为这可以同等应用于其他地方的高血压患者吗？例如亚洲的中国患者？早期干预策略而不是越低越好，这是我们可以应用于中国患者的策略吗？
 

    Prof. Kjeldson: I would certainly say so since there have been Chinese patients in many of these trials.  From my own case I was coordinating the VALUE trial and we had a lot of patients in China.  I think data are very applicable to patients in Asia and in China.  Also in the United States we see something similar.  We have had data from data from the ACCORD trial this winter and taking down blood pressure too much in the higher risk patients didn’t improve the prognosis but rather it was found to cause side-effects， although there was some benefit for stroke.

    Kjeldson教授：我当然会这么说，因为在这些试验中很多都有中国患者。从我自己来说，我正在协调VALUE试验，我们在中国有很多患者。我想数据对在亚洲和中国的患者非常适用。在美国我们也观察到相似的情况。这个冬天我们已经拿到来自ACCORD试验的数据，在较高危的患者中将血压降低过多并未改善预后，而是被发现导致不良反应，尽管对卒中有一些益处。